循环肿瘤DNA在卵巢癌中的研究进展

摘要/Abstract

摘要：随着分子生物学技术的不断发展，循环肿瘤DNA（ctDNA）在恶性肿瘤的诊治方面显示出一定的价值，二代测序技术的出现使血浆ctDNA检测更为精准、快速。ctDNA凭借其安全、非侵入性等优点在卵巢癌的早期诊断、病情监测、疗效评估、指导用药等方面发挥了一定作用。尽管目前血浆ctDNA检测的应用仍存在不足，但随着测序技术的不断发展，血浆ctDNA在卵巢癌的诊断、个性化治疗及预后评估等方面将发挥越来越重要的作用。

关键词:卵巢肿瘤,循环肿瘤DNA

Abstract:With the continued development of molecular biology technologies, circulating tumor DNA (ctDNA) has shown certain value in the diagnosis and treatment of malignant tumors. The emergence of next generation sequencing technology makes ctDNA detection more accurate and rapid. ctDNA plays a certain role in the early diagnosis, disease monitoring, therapeutic evaluation and medication guide of ovarian cancer by virtue of its safety and noninvasiveness. The application of ctDNA detection is insufficient at present, but with the continuous development of sequencing technology, ctDNA will play increasingly important roles in the diagnosis, personalized treatment and prognosis evaluation of ovarian cancer.

Key words:Ovarian neoplasms,Circulating tumor DNA

袁秋月,乔慧敏,张盛苗,夏宝国,毕淑娜,陈龙. 循环肿瘤DNA在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2019, 46(1): 57-60.

Yuan Qiuyue, Qiao Huimin, Zhang Shengmiao, Xia Baoguo, Bi Shuna, Chen Long. Research progress of circulating tumor DNA in ovrian cancer[J]. Journal of International Oncology, 2019, 46(1): 57-60.

参考文献

［1］ Gold B, Cankovic M, Furtado LV, et al. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology［J］. J Mol Diagn, 2015, 17(3): 209-224. DOI: 10.1016/j.jmoldx.2015.02.001. ［2］ Giannopoulou L, KasimirBauer S, Lianidou ES. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA［J］. Clin Chem Lab Med, 2018, 56(2): 186197. DOI: 10.1515/cclm20170019. ［3］ Campan M, Moffitt M, Houshdaran S, et al. Genomescale screen for DNA methylationbased detection markers for ovarian cancer［J］. PLoS One, 2011, 6(12): e28141. DOI: 10.1371/journal.pone.0028141. ［4］ Han LY, Fan YC, Mu NN, et al. Aberrant DNA methylation of Gproteincoupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B virus associated hepatocellular carcinoma［J］. Int J Med Sci, 2014, 11(2): 164-171. DOI: 10.7150/ijms.6745. ［5］ Schrock AB, Welsh A, Chung JH, et al. Hybrid capturebased genomic profiling of circulating tumor DNA from patients with advanced nonsmall cell lung cancer［J］. J Thorac Oncol, 2018, pii: S15560864(18)332052. DOI: 10.1016/j.jtho.2018.10.008. ［6］ GarciaMurillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer［J］. Sci Transl Med, 2015, 7(302): 302ra133. DOI: 10.1126/scitranslmed.aab0021. ［7］ Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage Ⅱ colon cancer［J］. 2016, 8(346): 346ra92. DOI: 10.1126/scitranslmed.aaf6219. ［8］ Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments［J］. Curr Oncol Rep, 2015, 17(4): 15. DOI: 10.1007/s11912-015-0438-0. ［9］ Pécuchet N, Zonta E, Didelot A, et al. Baseposition error rate analysis of nextgeneration sequencing applied to circulating tumor DNA in nonsmall cell lung cancer: a prospective study［J］. PLoS Med, 2016, 13(12): e1002199. DOI: 10.1371/journal.pmed.1002199. ［10］ Hou H, Yang X, Zhang J, et al. Discovery of targetable genetic alterations in advanced nonsmall cell lung cancer using a nextgeneration sequencingbased circulating tumor DNA assay［J］. Sci Rep, 2017, 7(1): 14605. DOI: 10.1038/s41598-017-14962-0. ［11］ Ma F, Zhu W, Guan Y, et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with antiHER2 therapy［J］. Oncotarget, 2016, 7(40): 66020-66031. DOI: 10.18632/oncotarget.11791. ［12］ Giannopoulou L, KasimirBauer S, Lianidou ES. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA［J］. Clin Chem Lab Med, 2018, 56(2): 186-197. DOI: 10.1515/cclm-2017-0019. ［13］ Diamandis EP, Fiala C. Can circulating tumor DNA be used for direct and early stage cancer detection?［J］. F1000Res, 2017, 6: 2129. DOI: 10.12688/f1000research.13440.1. ［14］ Fader AN, Wang Y, Papadapoulos N, et al. Detection of tumorderived DNA with combination Pap smear and plasma testing in women with primary ovarian cancer: a potential screening test on the horizon?［J］. Gynecol Oncol, 2017, 145 Suppl 1: 24-25. DOI: 10.1016/j.ygyno.2017.03.071. ［15］ Wu Y, Zhang X, Lin L, et al. Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer［J］. Asian Pac J Cancer Prev, 2014, 15(3): 11711176. ［16］ Cohen PA, Flowers N, Tong S, et al. Abnormal plasma DNA profiles in early ovarian cancer using a noninvasive prenatal testing platform: implications for cancer screening［J］. BMC Med, 2016, 14(1): 126. DOI: 10.1186/s12916-016-0667-6. ［17］ Lee HY, Lee SW, Na GH, et al. Abstract B04: early detection of ovarian cancer recurrence using p53mutated circulating tumor DNA as noninvasive biomarkers［J］. Clin Cancer Res, 2016, 22 Suppl 2: Abstract nr B04. DOI: 10.1158/1557-3265.OVCA15-B04. ［18］ Morikawa A, Hayashi T, Shimizu N, et al. PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma［J］. Oncotarget, 2018, 9(20): 15266-15274. DOI: 10.18632/oncotarget.24555. ［19］ Pereira E, CamachoVanegas O, Anand S, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers［J］. PLoS One, 2015, 10(12): e145754. DOI: 10.1371/journal.pone.0145754. ［20］ Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed highgrade serous ovarian carcinoma: a retrospective study［J］. PLoS Med, 2016, 13(12): e1002198. DOI: 10.1371/journal.pmed.1002198. ［21］ Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients［J］. Int J Cancer, 2015, 136(9): 2158-2165. DOI: 10.1002/ijc.29265. ［22］ Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer［J］. Ann Oncol, 2015, 26(8): 1715-1722. DOI: 10.1093/annonc/mdv177. ［23］ Giannopoulou L, Mastoraki S, Buderath P, et al. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with highgrade serous ovarian cancer［J］. Gynecol Oncol, 2018, 150(2): 355-360. DOI: 10.1016/j.ygyno.2018.05.026. ［24］ Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinumsensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebocontrolled, doubleblind, phase 2 trial［J］. Lancet Oncol, 2016, 17(11): 1579-1589. DOI: 10.1016/S1470-2045(16)30376-X. ［25］ Christie EL, Fereday S, Doig K, et al. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with highgrade serous ovarian cancer［J］. J Clin Oncol, 2017, 35(12): 1274-1280. DOI: 10.1200/JCO.2016.70.4627.

[1]	龚艳, 陈洪雷.微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	刘博翰, 黄俊星.液体活检技术在食管鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 105-108.
[3]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[4]	安荣, 刘美华, 王佩晨, 王晓慧.Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[5]	李晨曦, 赵宏伟.二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[6]	杨丽蓉, 王羽丰.预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[7]	李晨曦, 赵宏伟.PARP抑制剂治疗铂耐药卵巢癌的研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 180-183.
[8]	李哲丰, 李洁, 赵晓婷, 岳文涛.GLDC通过PI3K/Akt/mTOR通路调控卵巢癌细胞的增殖与凋亡[J]. 国际肿瘤学杂志, 2021, 48(12): 716-722.
[9]	关若丹, 摘译.奥拉帕利对携带BRCA突变的新诊断晚期卵巢癌、原发性腹膜癌、输卵管癌患者维持治疗的有效性研究:SOLO1试验的亚组分析(摘译)[J]. 国际肿瘤学杂志, 2021, 48(12): 764-768.
[10]	郑静, 姚胜, 沈文洁, 孙志佳, 赵辉, 付艳, 高珂, 杜楠.腹腔灌注贝伐珠单抗联合白蛋白紫杉醇和卡铂治疗卵巢癌所致癌性腹腔粘连的临床探讨[J]. 国际肿瘤学杂志, 2021, 48(11): 660-665.
[11]	杨立芬, 宋伟, 许大伟, 武军, 高然.miR-103a-3p/CHI3L1在卵巢癌细胞增殖和血管拟生中的作用机制[J]. 国际肿瘤学杂志, 2020, 47(6): 333-339.
[12]	杜明丽, 李桂香, 吴文娟, 赵磊.循环肿瘤DNA在转移性黑色素瘤靶向治疗及免疫治疗中的应用[J]. 国际肿瘤学杂志, 2020, 47(6): 381-384.
[13]	薛晨, 赵月, 石光, 唐艳.PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(5): 312-315.
[14]	杨怡婷, 程忠平.炎症细胞因子在卵巢上皮癌化疗耐药中的作用[J]. 国际肿瘤学杂志, 2020, 47(4): 249-251.
[15]	樊阳阳, 王影, 袁峰, 杜善平, 贺荣荣, 加燕.MALAT1靶向miR-142-3p在卵巢癌化疗耐药中的机制研究[J]. 国际肿瘤学杂志, 2020, 47(2): 82-89.